PSMA-PET与MR引导前列腺SBRT联合局部加量后的PSA与PSMA动力学:2期PROBE试验结果
6个月时79%患者PSA<0.1 ng/mL,12个月时50%;PSMA完全缓解率从SBRT完成时17%升至9–12个月65%,未见≥3级泌尿生殖/胃肠道毒性。
要点
- 6个月时79%患者PSA<0.1 ng/mL,12个月时50%。
- PSMA完全缓解率从SBRT完成时17%升至9–12个月65%。
- 3–6个月达完全缓解者平均PSA更低(0.04 vs 0.3 ng/mL,P=.009)。
核心结论
- PSMA-PET与MR引导的前列腺SBRT联合优势病灶加量可实现深度PSA下降、渐进性PSMA动力学变化及良好安全性。
- 6个月PSA<0.1 ng/mL可能预测PSMA完全缓解,3–6个月早期PSMA完全缓解可能预测持久PSA反应。
研究设计与样本
- 治疗方案为5次SBRT(前列腺36.25 Gy,PSMA/MRI定义的优势前列腺内病灶40–42.5 Gy)联合6个月雄激素剥夺治疗。
- PSA动力学基于每3个月PSA检测;采用68Ga-PSMA-PET/CT在SBRT完成时、完成后3–6个月及9–12个月评估代谢反应(adapted PET Response Criteria in Solid Tumors)。
- 毒性按美国国家癌症研究所常见不良事件评价标准v5.0报告累积泌尿生殖/胃肠道毒性。
主要发现
- 6个月时79%患者达到PSA<0.1 ng/mL,12个月时50%。
- 平均SUVmax从治疗前12.2(范围4.0–39.6)降至3–6个月3.2、9–12个月1.8。
- 完全缓解率从SBRT完成时17%升至3–6个月48%、9–12个月65%。
- 3–6个月达完全缓解者平均PSA更低(0.04 vs 0.3 ng/mL,P=.009);6个月PSA<0.1 ng/mL者12个月达完全缓解比例更高(76% vs 28%,P=.003)。
- 4例(14%)观察到早期SUV「flare」,至9–12个月消退;未见≥3级泌尿生殖/胃肠道毒性。
关键数值与推荐
- PSA<0.1 ng/mL:6个月79%、12个月50%。
- PSMA完全缓解率:SBRT完成时17%、3–6个月48%、9–12个月65%。
- 3–6个月达完全缓解者平均PSA 0.04 vs 0.3 ng/mL(P=.009)。
- 6个月PSA<0.1 ng/mL者12个月完全缓解率76% vs 28%(P=.003)。
- 早期SUV flare发生率14%(4例),9–12个月消退。
临床怎么用
- PSMA-PET与MR引导SBRT联合优势病灶加量可作为中高危局限期前列腺癌的治疗选择,需结合短期雄激素剥夺治疗。
- 治疗后6个月PSA<0.1 ng/mL及3–6个月PSMA完全缓解可作为潜在生物标志物,用于风险适应策略的进一步评估。
- 早期SUV flare需注意识别,以免误判为治疗失败。
局限性
- 原文未报告样本量以外的统计效能或随访时长信息。
- 原文未报告对照组或随机比较。
- 原文未报告长期生化控制或生存结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) kinetics following PSMA-positron emission tomography (PET) and magnetic resonance (MR) guided stereotactic body radiation therapy (SBRT) and short-term androgen deprivation therapy with dominant intraprostatic lesion (DIL) boost in localized prostate cancer. METHODS AND MATERIALS: This prespecified analysis from the phase 2 PROBE trial (IRB approval: IEC 900917) included patients with intermediate- or high-risk prostate cancer treated with 5-fraction SBRT (36.25 Gy to prostate; 40 to 42.5 Gy to PSMA/MRI-defined DIL) and 6 months of androgen deprivation therapy. PSA kinetics relied on 3-monthly PSA levels. Longitudinal metabolic response, based on the adapted PET Response Criteria in Solid Tumors, was assessed using 68Ga-PSMA-PET/computed tomography done at SBRT completion, 3 to 6 months, and 9 to 12 months after SBRT completion. Cumulative genitourinary/gastrointestinal toxicities were reported per National Cancer Institute Common Terminology Criteria for Adverse Events v5.0. RESULTS: Thirty enrolled patients (54% intermediate risk, 46% high risk) were included. A PSA <0.1 ng/mL was achieved in 79% of patients at 6 months and 50% at 12 months. The mean maximum standardized uptake value (SUVmax) decreased from 12.2 (range, 4.0-39.6) pretreatment to 3.2 at 3 to 6 months and 1.8 at 9 to 12 months. Complete response (CR) rates increased from 17% at SBRT completion to 48% at 3 to 6 months and 65% at 9 to 12 months. Patients achieving CR at 3 to 6 months reached a lower mean PSA (0.04 vs 0.3 ng/mL, P = .009). Those with PSA <0.1 ng/mL at 6 months were more likely to attain CR at 12 months (76% vs 28%, P = .003). An early standardized uptake value (SUV) "flare" was observed in 4 (14%) patients, resolving by 9 to 12 months. No National Cancer Institute Common Terminology Criteria for Adverse Events grade ≥3 genitourinary/gastrointestinal toxicity was seen. CONCLUSIONS: PSMA-PET and MR guided prostate SBRT with DIL boost achieved deep PSA nadirs, gradual PSMA kinetics, and a favorable safety profile. About 80% of patients achieved a PSA <0.1 ng/mL at 6 months, with two-thirds achieving CR by 12 months post-SBRT. Achieving a PSA <0.1 ng/mL could potentially predict PSMA-CR. Early PSMA-CR at 3 to 6 months may predict durable PSA response and warrants further evaluation as a biomarker for risk-adapted strategies in localized prostate cancer.
引用
- Singh M, Ghosh S, Katdare A, et al. PSA and PSMA Kinetics After PSMA-PET and MR Guided Prostate Stereotactic Body Radiation Therapy With Focal Boost: Results From the Phase 2 PROBE Trial. Int J Radiat Oncol Biol Phys. 2026. PMID: 41759677. doi:10.1016/j.ijrobp.2026.02.230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。